Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endocannabinoid system (ECS) is a complex neuromodulatory network involved in maintaining physiological homeostasis across various systems, including the nervous, immune, and endocrine systems. It comprises endocannabinoids, cannabinoid receptors (CB1 and CB2), and enzymes responsible for their synthesis and degradation. The ECS regulates a wide range of functions, including appetite, pain, mood, memory, and immune response. Dysregulation of the ECS has been implicated in various diseases, making it a potential therapeutic target.
Endogenous ligands (endocannabinoids) bind to cannabinoid receptors (CB1 and CB2) and other related receptors, modulating downstream cellular pathways. Exogenous cannabinoids (e.g., THC) mimic the action of endocannabinoids, primarily activating CB1 receptors.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endocannabinoid System (ECS).